Literature DB >> 16463426

Scleroderma treatment differs between experts and general rheumatologists.

Janet E Pope1, Janine M Ouimet, Adriana Krizova.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16463426     DOI: 10.1002/art.21714

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  5 in total

1.  Connective tissue diseases: New evidence-based guidelines for treating SSc.

Authors:  Janet E Pope
Journal:  Nat Rev Rheumatol       Date:  2009-06       Impact factor: 20.543

2.  Connective tissue disease: Reflections on the EULAR recommendations for the treatment of systemic sclerosis.

Authors:  Janet E Pope
Journal:  Nat Rev Rheumatol       Date:  2017-01-05       Impact factor: 20.543

3.  Drug compliance in patients with systemic scleroderma.

Authors:  Lucie Hromadkova; Tomas Soukup; Eva Cermakova; Jiri Vlcek
Journal:  Clin Rheumatol       Date:  2012-08-09       Impact factor: 2.980

4.  High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy.

Authors:  Nicolas Hunzelmann; Pia Moinzadeh; Ekkehard Genth; Thomas Krieg; Walter Lehmacher; Inga Melchers; Michael Meurer; Ulf Müller-Ladner; Thorsten M Olski; Christiane Pfeiffer; Gabriela Riemekasten; Eckhard Schulze-Lohoff; Cord Sunderkoetter; Manfred Weber
Journal:  Arthritis Res Ther       Date:  2009-03-04       Impact factor: 5.156

Review 5.  Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses.

Authors:  Fotini B Karassa; Konstantinos I Bougioukas; Eleftherios Pelechas; Anastasia Skalkou; Evangelia Argyriou; Anna-Bettina Haidich
Journal:  PLoS One       Date:  2022-08-03       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.